CN108503689B - Anti-platelet aggregation polypeptide KM6 - Google Patents
Anti-platelet aggregation polypeptide KM6 Download PDFInfo
- Publication number
- CN108503689B CN108503689B CN201710557834.6A CN201710557834A CN108503689B CN 108503689 B CN108503689 B CN 108503689B CN 201710557834 A CN201710557834 A CN 201710557834A CN 108503689 B CN108503689 B CN 108503689B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- platelet
- platelet aggregation
- adp
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
An anti-platelet aggregation polypeptide KM 6. The invention belongs to the technical field of medical biology, and particularly relates to a novel polypeptide with a platelet aggregation inhibiting effect. The polypeptide is polypeptide KM6 consisting of 10 amino acids, has the sequence of polypeptide of SEQ ID NO. 1, has the sequence of Gln-Leu-Ser-Asn-Gly-Asn-Arg-Thr-Leu-Thr, and has the molecular weight of 1103.19 Da. The polypeptide has a remarkable inhibiting effect on platelet aggregation induced by collagen, ADP and arachidonic acid, can be used for exploring the influence of the polypeptide and other platelet activators (epinephrine, ristocetin and the like) on the platelet and related functions, and can also be used for monitoring the conventional antiplatelet treatment.
Description
Technical Field
The invention belongs to the technical field of medical biology, and particularly relates to a novel polypeptide with a platelet aggregation inhibiting effect.
Background
Cardiovascular and cerebrovascular diseases mainly comprise common diseases such as acute myocardial infarction, cerebral infarction, pulmonary infarction, ischemic heart disease, cerebral apoplexy and the like, seriously threaten the health and the life of human beings and are the first cause of death of residents in China [1 ]. Platelet activation is an important initiation factor in the process of occurrence and development of cardiovascular and cerebrovascular diseases, and platelet activation, adhesion and aggregation to thrombosis are a series of cascade reactions, which not only play a key role in the physiological hemostasis process, but also participate in pathological processes such as thrombosis, tissue repair and the like [2,3 ]. Platelet aggregation plays a central role in thrombus formation. The inducers of platelet aggregation mainly include: collagen, arachidonic acid, ADP, thrombin, etc.
1. Collagen-induced platelet activation
When collagen is exposed by damage to vascular endothelial cells or plaque rupture, platelet membrane protein binding to the exposed collagen or activated vWF is a key step in initiating thrombosis. The surface of the platelet is provided with two specific sequences of membrane protein GPVI and integrin-alpha 2 beta 1 for recognizing collagen, thereby firmly binding the collagen. Among them, GPVI is a collagen signal transduction receptor involved in integrin- α 2 β 1-regulated signal transduction and platelet activation and aggregation after platelet adhesion [4-7 ]. Under the combined action of collagen and two membrane proteins, the activation pathway of integrin alphaIIb beta 3 is finally activated, which causes platelet aggregation and release [8,9 ].
2. Arachidonic acid-induced platelet activation
Increased levels of intracellular Ca2+ in platelets can cause activation of phospholipase A2, which in turn frees arachidonic acid from phospholipid membranes. Arachidonic acid synthesizes thromboxane A2(TXA2) under the action of cyclooxygenase-1, and after TXA2 is combined with TXA2 receptor on platelet membrane [10], the arachidonic acid is combined with specific G protein-coupled receptors Gq and G13 to activate platelets. TXA2 is not only a strong agonist of platelet activation and vascular smooth muscle contraction, it can also amplify platelet activation signals caused by low doses of thrombin and ADP, among others. TXA2 activates PLC β downstream of it upon binding to the receptor, causing activation of IP3, DAG, G13 and the signaling pathways associated with these proteins [11], ultimately causing platelet deformation and release of intra-platelet granules [12 ].
3. ADP-induced platelet activation
ADP is a major component of dense granule release in activated platelets, and plays a very important role in platelet activation and aggregation processes. ADP receptors are mainly P2Y1, P2Y12 and P2X 1. Wherein P2Y1 is a G protein coupled transmembrane receptor, after ADP is combined with P2Y1 receptor, P2Y1 receptor is coupled with Gq protein to activate phospholipase C, thereby leading Ca2+ to flow into the cell from the extracellular direction, and the increase of the intracellular Ca2+ concentration activates protein kinase C to cause platelet deformation and aggregation [13 ]. P2Y12 is a G protein-coupled receptor [14], and is important not only for ADP-induced irreversible platelet aggregation, but also for ADP-mediated generation of TXA 2. The P2X1 protein receptor is a ligand-gated ion channel, is mainly responsible for the rapid calcium influx caused by ADP, and has weak action in platelet aggregation [15 ].
4. Thrombin-induced platelet activation
Thrombin is the most potent platelet agonist, which activates platelets by binding to platelet membrane surface Protease Activated Receptors (PARs). Human platelets express PAR-1 and PAR-4[16], either of which is activated to cause platelet aggregation and particle release [17 ]. Research shows that PAR-1 is sensitive to low-concentration thrombin, and PAR-4 triggers the activation and aggregation of platelets only in a high-concentration thrombin environment; and thrombin cleaves PAR-4 20 to 70 times slower than PAR-1, and thus PAR-1 is the most important receptor for thrombin to cause platelet activation [18,19 ]. Studies have shown that PAR-1 is coupled to Gq, G13, Gi/z and PAR-4 is coupled to Gq, G13 only, linking the coagulation signal to the intracellular signaling pathway, resulting in activation of PLC β, PI3K and Ras-like Rho kinase, leading to hydrolysis of IP3, calcium mobilization and activation of PKC [17,20 ].
However, the existing antiplatelet drugs not only have side effects such as bleeding tendency (cerebral hemorrhage, massive hemorrhage of digestive tract) and the like [21], but also have resistance or low response phenomena in clinical application, and adverse ischemic events still occur; meanwhile, the drugs have single action mechanism and have certain limitation on antiplatelet action: such as aspirin, irreversibly blocks COX-1 synthesis, thereby inhibiting platelet activation, aggregation [10,22 ]; clopidogrel irreversibly inhibits ADP binding to its receptor P2Y12, inhibiting ADP-induced platelet aggregation [23 ]; ticagrelor reversibly interacts with the ADP-P2Y12 receptor, also inhibiting ADP-induced platelet aggregation [24 ]; vorapaxar and Atopaxar are PAR-1 inhibitors now in clinical trials that inhibit thrombin-induced platelet aggregation [25,26 ]; the abciximab, tirofiban and eptifibatide are all GP IIb/IIIa receptor antagonists [27 ]. Clinically, in order to increase the curative effect and reduce the side effect, antiplatelet drugs with different action mechanisms are used in combination. Therefore, it is of great significance to search for a safer and more reliable novel antiplatelet drug.
Disclosure of Invention
The technical problem to be solved by the invention is to provide the anti-platelet aggregation polypeptide KM6, which has a remarkable inhibiting effect on platelet aggregation induced by collagen, ADP and arachidonic acid, can be used for exploring the effect of the polypeptide KM6 and other platelet activators (epinephrine, ristocetin and the like) on platelets and the influence of the polypeptide KM6 and other platelet activators on related functions, and can also be used for monitoring the existing anti-platelet therapy.
The technical scheme adopted for realizing the above purpose of the invention is as follows: the polypeptide is polypeptide KM6 consisting of 10 amino acids, has the sequence of polypeptide of SEQ ID NO. 1, has the sequence of Gln-Leu-Ser-Asn-Gly-Asn-Arg-Thr-Leu-Thr, and has the molecular weight of 1103.19 Da. After the polypeptide is synthesized, the high performance liquid chromatography and mass spectrometry technology verify that the synthesized substrate is a complete amino acid sequence (figure 1 and figure 2).
The polypeptide KM6 for resisting platelet aggregation can be applied to preparation of a preparation with an inhibitory effect on platelet aggregation.
The anti-platelet aggregation polypeptide KM6 can be applied to preparation of anti-platelet aggregation and cardiovascular disease treatment medicines.
The polypeptide in the medicine for resisting platelet aggregation and treating cardiovascular diseases, which is prepared from the polypeptide KM6 for resisting platelet aggregation, is an active ingredient and contains one or more pharmaceutically acceptable carriers.
The biological properties of the polypeptides provided by the invention can foresee many applications thereof.
The invention can be used for preparing medicaments for resisting platelet aggregation and treating cardiovascular diseases.
The present invention may be directed to methods for treating a bleeding disorder: evaluating platelet aggregation function, evaluating the effectiveness of existing hemostatic treatments (hemostatic bandages, hemostatic adhesives, etc.).
The present invention may be directed to methods for treating thrombotic disorders: evaluating platelet aggregation function, evaluating effectiveness of current or future treatment of antiplatelet therapy (such as aspirin, clopidogrel, ticagrelor, etc.); at the same time, it can be used for antithrombotic treatment due to its platelet aggregation-inhibiting effect.
The polypeptide provided by the invention has the effects of obviously inhibiting platelet aggregation activity induced by ADP, collagen and arachidonic acid through tests, presents a dose-dependent relationship, and has no obvious influence on platelet aggregation caused by thrombin (fig. 3 and 4). The polypeptide is not limited to inhibiting platelet aggregation induced by ADP, collagen and arachidonic acid, can be used for exploring the influence of the polypeptide and other platelet activators (adrenalin, ristocetin and the like) on the effects and related functions of platelets, and can also be used for monitoring the conventional antiplatelet treatment.
The invention relates to a polypeptide KM6 consisting of 10 amino acids, which is used for determining the effect on platelet aggregation activity through an in vitro human platelet aggregation experiment. Experiments prove that the polypeptide has a remarkable inhibiting effect on platelet aggregation induced by collagen, ADP and arachidonic acid. The novel polypeptide KM6 sequence related to the invention has not been reported so far.
Drawings
The following drawings are included to illustrate specific embodiments of the invention and are not intended to limit the scope of the invention as defined by the claims.
FIG. 1 is a high performance liquid chromatography purification diagram of a polypeptide provided by the present invention: the peak value C was KM 6.
FIG. 2 is a secondary mass spectrum of peak C (i.e., KM 6).
FIG. 3 is a graph showing the effect of KM6 on collagen, ADP, arachidonic acid, and thrombin-induced platelet aggregation, which was measured by optical turbidimetry. After incubation of platelet-rich plasma with different concentrations of KM6 for 20 minutes at 37 ℃, collagen (A), arachidonic acid (B), ADP (C), thrombin (D) inducer were added and the platelet aggregation curves (mean, n.gtoreq.4) were recorded.
FIG. 4 is a bar graph showing the effect of KM6 on collagen, ADP, arachidonic acid, and thrombin-induced platelet aggregation, as measured by optical turbidimetry. The influence of different concentrations of KM6 on platelet aggregation induced by thrombin, ADP, collagen and arachidonic acid (mean. + -. standard error, n is not less than 4). (P < 0.05), (P < 0.01).
Detailed Description
Example (b): the polypeptide KM6 provided by the invention inhibits human platelet aggregation induced by collagen, ADP and arachidonic acid in vitro
The effect of KM6 on collagen, arachidonic acid, thrombin, ADP-induced platelet aggregation was evaluated by optical turbidimetric assay.
Platelets were collected from healthy volunteers provided from our hospital blood bank with signed consent.
(1) Diluting the polypeptide with deionized water containing 15% DMSO to adjust the final concentration of the polypeptide to 10 mM; an equal volume of 15% DMSO polypeptide-free deionized water was added to the control experiment.
(2) Taking 100 μ l of the apheresis platelets, diluting the platelets with 300 μ l of modified Tyrode's buffer (137mM NaCl,27mM KCl,1mM MgCl2,0.42mM NaH2PO4,5.5mM Glucose,5.55mM HEPES, 0.25% Bovine Serumalbumin, pH 7.4) to obtain platelet-rich plasma, wherein the number of platelets is adjusted to 2.5X 108 platelets/mL; separately, 100. mu.l of the collected platelet was diluted with 300. mu.l of Tyrode's buffer solution and centrifuged at 10000rpm for 10 minutes to obtain a supernatant as platelet poor plasma.
(3) After 400. mu.l of the platelet resuspension was aspirated and preheated at 37 ℃ for 5min, KM6 (0. mu.M, 1. mu.M, 25. mu.M, 50. mu.M, 100. mu.M, 200. mu.M, 500. mu.M) was added to the above platelet resuspension and incubated at 37 ℃ for 20 min. Opening a platelet aggregation instrument, setting parameters as required, placing a magnetic rod in the incubated platelet-rich plasma, inserting a platelet reaction cup with a magnetic stirring rod into a detection hole of a machine, placing the platelet reaction cup in a test area of the platelet aggregation instrument, adjusting zero, adding collagen, arachidonic acid, thrombin and ADP activator, observing the influence of KM6 on platelet aggregation caused by different activators at 37 ℃ and 1200rpm for 5-10 min. Each KM6 concentration group was repeated at least four times and averaged. Recording the platelet aggregation profiles and plotting the corresponding bar graphs on the basis of the platelet aggregation rates (FIG. 3, FIG. 4)
(4) Experimental data were processed with SPSS 21.0 statistical software. Results are expressed as mean ± sem. Performing homogeneous variance test for multiple groups, performing one-way ANOVA for homogeneous variance, and performing LSD (least-significant difference) for pairwise comparison; if the variance is not uniform, the Tamhane' sT2 test is carried out, and the t test is adopted for pairwise comparison. P < 0.05 the difference was considered statistically significant.
From the above results, it can be seen that, within the effective dosage range, the polypeptide KM6 provided by the present invention has significant inhibitory effect on human platelet aggregation induced by collagen, ADP, arachidonic acid, and exhibits a dose-dependent relationship, without significant effect on platelet aggregation induced by thrombin.
Reference documents:
1. chenwei, Gansulin, Liuliseng, Zhumandilu, Wangwen, et al (2016) (summary of report 2015 on cardiovascular disease in China) J.J.521-Chong 528.
2.George JN(2000)Platelets.Lancet 355:1531-1539。
3.Jurk K,Kehrel BE(2010)[Pathophysiology and biochemistry of platelets].Internist(Berl)51:1086,1088-1092,1094。
4.Coller BS,Beer JH,Scudder LE,Steinberg MH(1989)Collagen-platelet interactions:evidence for a direct interaction of collagen with plateletGPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated byadhesive proteins.Blood 74:182-192。
5.Moroi M,Jung SM(2004)Platelet glycoprotein VI:its structure and function.Thromb Res 114:221-233。
6.Puett D,Wasserman BK,Ford JD,Cunningham LW(1973)Collagen-mediated platelet aggregation.Effects of collagen modification involving the proteinand carbohydrate moieties.J Clin Invest 52:2495-2506。
7.Tsuji M,Ezumi Y,Arai M,Takayama H(1997)A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as acollagen receptor in human platelets.J Biol Chem 272:23528-23531。
8.Li Z,Delaney MK,O'Brien KA,Du X(2010)Signaling during platelet adhesion and activation.ArteriosclerThromb Vasc Biol 30:2341-2349。
9.Zahid M,Mangin P,Loyau S,Hechler B,Billiald P,et al.(2012)The future of glycoprotein VI as an antithrombotic target.J Thromb Haemost 10:2418-2427。
10.Halvorsen S,Andreotti F,ten Berg JM,Cattaneo M,Coccheri S,et al.(2014)Aspirin therapy in primary cardiovascular disease prevention:a positionpaper of the European Society of Cardiology working group on thrombosis.J AmColl Cardiol 64:319-327。
11.Chakraborty R,Pydi SP,Gleim S,Bhullar RP,Hwa J,et al.(2013)New insights into structural determinants for prostanoid thromboxaneA2 receptor-and prostacyclin receptor-G protein coupling.Mol Cell Biol 33:184-193。
12.Bhavaraju K,Lakhani PR,Dorsam RT,Jin J,Hitchcock IS,et al.(2011)G(12/13)signaling pathways substitute for integrin alphaIIbbeta3-signaling forthromboxane generation in platelets.PLoS One 6:e16586。
13.Cattaneo M(2005)The P2 receptors and congenital platelet function defects.Semin Thromb Hemost 31:168-173。
14.Jin J,Kunapuli SP(1998)Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation.Proc NatlAcad Sci U S A 95:8070-8074。
15.Vial C,Hechler B,Leon C,Cazenave JP,Gachet C(1997)Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines.ThrombHaemost 78:1500-1504。
16.Coughlin SR(1999)How the protease thrombin talks to cells.Proc NatlAcad Sci U S A 96:11023-11027。
17.Hua Y,Keep RF,Gu Y,Xi G(2009)Thrombin and brain recovery after intracerebral hemorrhage.Stroke 40:S88-89。
18.Martorell L,Martinez-Gonzalez J,Rodriguez C,Gentile M,Calvayrac O,et al.(2008)Thrombin and protease-activated receptors(PARs)inatherothrombosis.Thromb Haemost 99:305-315。
19.Carrim N,Arthur JF,Hamilton JR,Gardiner EE,Andrews RK,et al.(2015)Thrombin-induced reactive oxygen species generation in platelets:A novel rolefor protease-activated receptor 4 and GPIbalpha.Redox Biol 6:640-647。
20.Sambrano GR,Weiss EJ,Zheng YW,Huang W,Coughlin SR(2001)Role of thrombin signalling in platelets in haemostasis and thrombosis.Nature 413:74-78。
21.Geisler T,Gawaz M,Steinhubl SR,Bhatt DL,Storey RF,et al.(2010)Current strategies in antiplatelet therapy--does identification of risk andadjustment of therapy contribute to more effective,personalized medicine incardiovascular disease Pharmacol Ther 127:95-107。
22.Tantry US,Mahla E,Gurbel PA(2009)Aspirin resistance.Prog Cardiovasc Dis 52:141-152.
23.Ray S(2014)Clopidogrel resistance:the way forward.Indian Heart J 66:530-534。
24.SamsteinRM,Josefowicz SZ,Arvey A,Treuting PM,Rudensky AY(2012)Extrathymic generation of regulatory T cells in placental mammals mitigatesmaternal-fetal conflict.Cell 150:29-38。
25.Morrow DA,Braunwald E,Bonaca MP,Ameriso SF,Dalby AJ,et al.(2012)Vorapaxar in the secondary prevention of atherothrombotic events.N Engl J Med366:1404-1413。
26.Tricoci P,Huang Z,Held C,Moliterno DJ,Armstrong PW,et al.(2012)Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.N Engl JMed 366:20-33。
27.Muniz-Lozano A,Rollini F,Franchi F,Angiolillo DJ(2013)Update on platelet glycoprotein IIb/IIIa inhibitors:recommendations for clinicalpractice.Ther Adv Cardiovasc Dis 7:197-213。
SEQUENCE LISTING
<110> first Hospital affiliated to Kunming medical university
<120> an anti-platelet aggregation polypeptide KM6
<140>
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 10
<212> PRT
<213> Artificial sequence
<400> 1
Gln Leu Ser Asn Gly Asn Arg Thr Leu Thr
1 5 10
Claims (3)
1. An anti-platelet aggregation polypeptide KM6, which is characterized in that: the polypeptide is polypeptide KM6 consisting of 10 amino acids, has the sequence of polypeptide of SEQ ID NO. 1, has the sequence of Gln-Leu-Ser-Asn-Gly-Asn-Arg-Thr-Leu-Thr, and has the molecular weight of 1103.19 Da.
2. The use of the anti-platelet aggregation polypeptide KM6 according to claim 1 in the preparation of a preparation having an inhibitory effect on platelet aggregation induced by human collagen, ADP and arachidonic acid in vitro.
3. Use according to claim 2, characterized in that: the polypeptide is an active ingredient and contains one or more pharmaceutically acceptable carriers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710557834.6A CN108503689B (en) | 2017-07-10 | 2017-07-10 | Anti-platelet aggregation polypeptide KM6 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710557834.6A CN108503689B (en) | 2017-07-10 | 2017-07-10 | Anti-platelet aggregation polypeptide KM6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108503689A CN108503689A (en) | 2018-09-07 |
| CN108503689B true CN108503689B (en) | 2019-12-31 |
Family
ID=63374410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710557834.6A Active CN108503689B (en) | 2017-07-10 | 2017-07-10 | Anti-platelet aggregation polypeptide KM6 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108503689B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112125953B (en) * | 2020-07-23 | 2022-09-16 | 昆明医科大学第一附属医院 | Polypeptide for resisting platelet aggregation |
| CN111870700B (en) * | 2020-08-12 | 2021-10-19 | 中国科学院昆明动物研究所 | Application of octadecyl modified R18-7AA polypeptide and derivative polypeptide thereof |
| CN111773376B (en) * | 2020-08-12 | 2022-06-24 | 中国科学院昆明动物研究所 | Application of octadecyl modified polypeptide in preparation of medicine for inhibiting platelet aggregation |
| CN113429459B (en) * | 2021-06-16 | 2022-07-26 | 昆明医科大学第一附属医院 | Anti-platelet polypeptide, pharmaceutical composition thereof and application thereof |
| CN113429457B (en) * | 2021-06-16 | 2022-07-26 | 昆明医科大学第一附属医院 | Polypeptide for resisting platelet aggregation and application thereof |
| CN116840485A (en) * | 2023-05-18 | 2023-10-03 | 河络新图生物科技(上海)有限公司 | Detection system, detection method and detection kit for detecting platelet function subpopulation PAC-1 marker, annexin-V marker and CD62P marker |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1512891A (en) * | 2001-04-06 | 2004-07-14 | Epitope sequences | |
| CN102911264A (en) * | 2005-11-04 | 2013-02-06 | 学校法人自治医科大学 | Platelet aggregation inhibitor composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003059379A2 (en) * | 2002-01-17 | 2003-07-24 | Pharmexa A/S | Immunogenic carcinoembryonic antigen (cea) |
| EP1495322A4 (en) * | 2002-04-05 | 2006-09-06 | Epimmune Inc | Heteroclitic analogs and related methods |
-
2017
- 2017-07-10 CN CN201710557834.6A patent/CN108503689B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1512891A (en) * | 2001-04-06 | 2004-07-14 | Epitope sequences | |
| CN102911264A (en) * | 2005-11-04 | 2013-02-06 | 学校法人自治医科大学 | Platelet aggregation inhibitor composition |
Non-Patent Citations (3)
| Title |
|---|
| Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach;Markus Schirle 等;《Eur. J. Immunol. 》;20001231;第30卷;第2216-2225页 * |
| Structure-Function Relationships in theActivation of Platelet Thrombin Receptors by Receptor-derived Peptides;Ralph R. Vassallo, Jr. 等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;19920325;第267卷(第9期);第6081-6085页 * |
| 新型抗血小板多肽类药物研究进展;柳亚敏 等;《药学进展》;20150930;第39卷(第9期);第666-670页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108503689A (en) | 2018-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108503689B (en) | Anti-platelet aggregation polypeptide KM6 | |
| Feng et al. | Inhibition of NLRP3 inflammasome: a prospective target for the treatment of ischemic stroke | |
| Cattaneo | P2Y12 receptors: structure and function | |
| Golebiewska et al. | Platelet secretion: From haemostasis to wound healing and beyond | |
| CN108503688B (en) | Anti-platelet aggregation polypeptide KM22 | |
| US8735353B2 (en) | Polypeptides and uses thereof | |
| Mascolo et al. | Renin-angiotensin system and Coronavirus disease 2019: A narrative review | |
| Hollenberg et al. | Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer | |
| Bhagwani et al. | When innate immunity meets angiogenesis—the role of toll-like receptors in endothelial cells and pulmonary hypertension | |
| CN108503692B (en) | Polypeptide PEP1 for promoting platelet aggregation | |
| Heinzmann et al. | Complementary roles of platelet αIIbβ3 integrin, phosphatidylserine exposure and cytoskeletal rearrangement in the release of extracellular vesicles | |
| Sveshnikova et al. | Platelet functional responses and signalling: the molecular relationship. Part 1: responses. | |
| Zhong et al. | NOD2-mediated P2Y12 upregulation increases platelet activation and thrombosis in sepsis | |
| CN108503694B (en) | Polypeptide 8496 for promoting platelet aggregation | |
| CN108570095B (en) | Polypeptide SITE2 for promoting platelet aggregation | |
| Shu et al. | Antimicrobial peptide cathelicidin-BF inhibits platelet aggregation by blocking protease-activated receptor 4 | |
| Ramachandran | Developing PAR1 antagonists: minding the endothelial gap | |
| Byskov et al. | Protease activated receptors (PAR)‐1 and‐2 mediate cellular effects of factor VII activating protease (FSAP). | |
| CN108503693B (en) | Polypeptide KM17 for promoting platelet aggregation | |
| Fang et al. | Helenine blocks NLRP3 activation by disrupting the NEK7-NLRP3 interaction and ameliorates inflammatory diseases | |
| Wei et al. | Inhibition of the interactions between metastatic human breast cancer cells and platelets by β-nitrostyrene derivatives | |
| Maugeri et al. | Platelet HMGB1 steers intravascular immunity and thrombosis | |
| CN107033220B (en) | Polypeptide KM13 for promoting platelet aggregation | |
| Li et al. | The Multifaceted Nature of Macrophages in Cardiovascular Disease | |
| Zhang et al. | The naphthoquinone plumbagin suppresses ADP-induced rat platelet aggregation through P2Y1-PLC signaling pathway. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |